Journal of Gynecologic Oncology · 2012 · 26 citations · 27 references
MedicineGynecologyOncologyBenign Gynecologic DisordersCancer ScreeningGynecologic OncologyBenign Ovarian TumorsBorderline Ovarian TumorsCancer BiomarkersOvarian CancerOvarian CystsTumor MarkersBiomarkersBiomarkers Of Ovarian FunctionCancer Antigen 125Ovarian Cancer BiomarkersOvarian Cancer DetectionOvarian Tumor BiomarkersPositive Predictive ValueTumor Marker Panels
OBJECTIVE: To determine the predictive accuracy of the combined panels of serum human tissue kallikreins (hKs) and CA-125 for the detection of epithelial ovarian cancer. METHODS: Serum specimens collected from 5 Indonesian centers and 1 Vietnamese center were analyzed for CA-125, hK6, and hK10 levels. A total of 375 specimens from patients presenting with ovarian tumors, which include 156 benign cysts, 172 epithelial ovarian cancers (stage I/II, n=72; stage III/IV, n=100), 36 germ cell tumors and 11 borderline tumors, were included in the study analysis. Receiver operating characteristic analysis were performed to determine the cutoffs for age, CA-125, hK6, and hK10. Sensitivity, specificity, negative, and positive predictive values were determined for various combinations of the biomarkers. RESULTS: The levels of hK6 and hK10 were significantly elevated in ovarian cancer cases compared to benign cysts. Combination of 3 markers, age/CA-125/hk6 or CA-125/hk6/hk10, showed improved specificity (100%) and positive predictive value (100%) for prediction of ovarian cancer, when compared to the performance of single markers having 80-92% specificity and 74-87% positive predictive value. Four-marker combination, age/CA-125/hK6/hK10 also showed 100% specificity and 100% positive predictive value, although it demonstrated low sensitivity (11.9%) and negative predictive value (52.8%). CONCLUSION: The combination of human tissue kallikreins and CA-125 showed potential for improving prediction of epithelial ovarian cancer in patients presenting with ovarian tumors.
27
Principles and Practice of Screening for Disease.
Annals of Internal Medicine · 1968 · 3.1K citations
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Robert C. Bast, Maryellen Feeney, Herbert Lazarus et al. · Journal of Clinical Investigation · 1981 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +17
[Principles and practice of mass screening for disease].
J M Wilson, Y G Jungner · PubMed · 1968 · 770 citations
Serum protein markers for early detection of ovarian cancer
Gil Mor, Irene Visintin, Yinglei Lai et al. · Proceedings of the National Academy of Sciences · 2005 · 523 citations · Full text
Medicine, Gynecology, Oncology +16